Results 31 to 40 of about 174,816 (264)

Predictive biomarkers of response to immune checkpoint inhibitors [PDF]

Farmacia Hospitalaria, 2020
Objective: The present paper provides a literature review aimed at identifying the tumor-dependent factors capable of influencing a subject’s response to immune checkpoint inhibitors, with a special emphasis on those that may act as predictive ...
María Sacramento Díaz-Carrasco, Eva González-Haba, Juana Inés García-Soler, Alberto Espuny-Miró   +3 more
doaj   +1 more source

Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer 
with EGFR Mutation

Chinese Journal of Lung Cancer, 2022
The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the first line treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but drug resistance will be acquired within 1-2 years, and the following treatment
Yue ZHU, Zhaoxia DAI
doaj   +1 more source

The Molecular Links between Cell Death and Inflammasome

Cells, 2019
Programmed cell death pathways and inflammasome activation pathways can be genetically and functionally separated. Inflammasomes are specialized protein complexes that process pro-inflammatory cytokines, interleukin-1β (IL-1β), and IL-18 to ...
Kwang-Ho Lee, Tae-Bong Kang
doaj   +1 more source

Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients

Frontiers in Medicine, 2023
BackgroundAnti-programmed cell death protein 1 (PD-1) monotherapy is one of the standard systemic therapies for advanced melanoma; however, the efficacy of salvage systemic therapies after PD-1 monotherapy failure (PD-1 MF), particularly in acral ...
Tatsuhiko Mori, Kenjiro Namikawa, Naoya Yamazaki, Yukiko Kiniwa, Osamu Yamasaki, Shusuke Yoshikawa, Takashi Inozume, Hiroshi Kato, Yasuo Nakai, Satoshi Fukushima, Tatsuya Takenouchi, Takeo Maekawa, Shigeto Matsushita, Atsushi Otsuka, Atsushi Otsuka, Motoo Nomura, Natsuki Baba, Taiki Isei, Shintaro Saito, Noriki Fujimoto, Ryo Tanaka, Takahide Kaneko, Yutaka Kuwatsuka, Taisuke Matsuya, Kotaro Nagase, Masazumi Onishi, Takehiro Onuma, Yasuhiro Nakamura   +27 more
doaj   +1 more source

Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response

Frontiers in Bioscience-Landmark
Lung cancer, the leading cause of cancer-related mortality worldwide, poses considerable therapeutic challenges due to the varied responses to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors.
Yuanyuan Xu, Yixing Tao, Hanbo Pan, Zhongjie Wang, Hui Wang, Qingquan Luo   +5 more
doaj   +1 more source

Research Progress on the Mechanism and Clinical Data of Cereblon 
in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells

Chinese Journal of Lung Cancer, 2021
Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell.
Jingjing GUO, Di MU, Ying HAN
doaj   +1 more source

PD-L1 and CD8+ T cell evaluation in breast cancers and their correlation with clinicopathological parameters

Journal of the Pakistan Medical Association
Objective: To determine the immunohistochemical expression of Programmed cell Death Ligand 1 and intratumoural cluster of differentiation-8-positive T lymphocyte count in primary breast cancer cases, and to ascertain their association with different ...
Sayher Kazmi, Sumayyah Shawana, Nighat Jamal   +2 more
doaj   +1 more source

Incidence and Risk Factors of Serious Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia: A CYP‐C Population‐Based Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteonecrosis (ON) is a debilitating complication of acute lymphoblastic leukemia (ALL) therapy. While numerous studies have explored its incidence and associated risk factors, investigations using large‐scale cohorts remain important to characterize ON across heterogeneous populations.
Noémie de Villiers, Chantal Éthier, Caroline Laverdière, Nathalie Alos, Thai Hoa Tran, Marie‐Claude Pelland‐Marcotte   +5 more
wiley   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Function‐driven design of a surrogate interleukin‐2 receptor ligand

FEBS Letters, EarlyView.
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang   +9 more
wiley   +1 more source